Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

286
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
286
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 Vaccine Reactogenicity Marks an Innate Inflammatory Response Associated With HLA Variation and Enhanced Protection.

Research square·2026
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Phenotype List String Grammar for Enhanced Protein and Antigen Reporting in the Immunogenetic Context.

HLA·2026
Same author

Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation.

Blood advances·2026
Same author

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Blood advances·2026
Same author

HLA matching in contemporary haematopoietic cell transplantation: Recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Jun 8, 2025

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.2K

Novel Scoring System for Ranking Hematopoietic Stem Cell Transplantation.

Lee Ann Baxter-Lowe1, Tao Wang2,3, Michelle Kuxhausen4

  • 1University of Southern California and Children's Hospital Los Angeles, Los Angeles, California, USA.

Clinical Transplantation
|November 8, 2024
PubMed
Summary

A new scoring system for human leukocyte antigen (HLA) mismatches in hematopoietic stem cell transplants (HSCT) did not significantly predict outcomes. However, HLA mismatches with no peptide binding differences (Peptide Score = 0) may indicate better transplant-related mortality, expanding permissive donor options.

Keywords:
HLA mismatchHSCTscoring systemunrelated donors

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.1K

Related Experiment Videos

Last Updated: Jun 8, 2025

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

15.2K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.7K
Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

7.1K

Area of Science:

  • Immunogenetics
  • Transplantation immunology
  • Hematology

Background:

  • Hematopoietic stem cell transplantation (HSCT) relies on human leukocyte antigen (HLA) matching for optimal outcomes.
  • Lack of universally accepted guidelines for ranking 7/8 HLA-matched unrelated donors poses challenges when HLA-matched donors are unavailable.
  • A novel scoring system was investigated to rank HLA mismatches in unrelated donor HSCT.

Purpose of the Study:

  • To investigate a novel scoring system for ranking single HLA Class I mismatches in 7/8 HLA-matched unrelated donor HSCT.
  • To assess the association of this scoring system with overall survival and acute graft-versus-host disease (GVHD).

Main Methods:

  • High-resolution HLA typing to identify amino acid mismatches in the HLA antigen-recognition domain.
  • Scoring of mismatches based on physicochemical properties affecting peptide binding, T-cell receptor docking, and HLA structure/function.
  • Analysis of a cohort of 2319 leukemia/myelodysplastic syndrome patients undergoing first unrelated donor HSCT.

Main Results:

  • The novel scoring system did not significantly correlate with transplant outcomes (overall survival, acute GVHD).
  • A Peptide Score of 0 (no peptide binding alteration) was associated with lower transplant-related mortality (TRM) (p=0.019).
  • HLA mismatches with Peptide Score = 0 included HLA-C*03:03/03:04 and other specific mismatches, previously suggested as permissive.

Conclusions:

  • HLA mismatches that do not alter peptide binding (Peptide Score = 0) may represent permissive mismatches, potentially expanding the donor pool.
  • Further research is required to validate these findings and explore alternative scoring systems for HLA mismatched donor selection.